Literature DB >> 29242297

Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas.

François Lemonnier1,2, Elsa Poullot2,3, Aurélie Dupuy1,2, Lucile Couronné4, Nadine Martin1,2, Laurianne Scourzic4, Virginie Fataccioli1,2,3, Julie Bruneau5, Rob A Cairns6, Tak W Mak6, Olivier A Bernard4, Laurence de Leval7, Philippe Gaulard8,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29242297      PMCID： PMC5830377          DOI： 10.3324/haematol.2017.167973

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Authors:  Cyril Quivoron; Lucile Couronné; Véronique Della Valle; Cécile K Lopez; Isabelle Plo; Orianne Wagner-Ballon; Marcio Do Cruzeiro; Francois Delhommeau; Bertrand Arnulf; Marc-Henri Stern; Lucy Godley; Paule Opolon; Hervé Tilly; Eric Solary; Yannis Duffourd; Philippe Dessen; Hélène Merle-Beral; Florence Nguyen-Khac; Michaëla Fontenay; William Vainchenker; Christian Bastard; Thomas Mercher; Olivier A Bernard
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

2.  Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.

Authors:  François Lemonnier; Lucile Couronné; Marie Parrens; Jean-Philippe Jaïs; Marion Travert; Laurence Lamant; Olivier Tournillac; Therese Rousset; Bettina Fabiani; Rob A Cairns; Tak Mak; Christian Bastard; Olivier A Bernard; Laurence de Leval; Philippe Gaulard
Journal:  Blood       Date:  2012-07-03       Impact factor: 22.113

3.  Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.

Authors:  Minoti Magotra; Ali Sakhdari; Paul J Lee; Keith Tomaszewicz; Karen Dresser; Lloyd M Hutchinson; Bruce A Woda; Benjamin J Chen
Journal:  Histopathology       Date:  2016-09-23       Impact factor: 5.087

4.  IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.

Authors:  Rob A Cairns; Javeed Iqbal; François Lemonnier; Can Kucuk; Laurence de Leval; Jean-Philippe Jais; Marie Parrens; Antoine Martin; Luc Xerri; Pierre Brousset; Li Chong Chan; Wing-Chung Chan; Philippe Gaulard; Tak W Mak
Journal:  Blood       Date:  2012-01-03       Impact factor: 25.476

5.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Terukazu Enami; Kenichi Yoshida; Yuichi Shiraishi; Ryohei Ishii; Yasuyuki Miyake; Hideharu Muto; Naoko Tsuyama; Aiko Sato-Otsubo; Yusuke Okuno; Seiji Sakata; Yuhei Kamada; Rie Nakamoto-Matsubara; Nguyen Bich Tran; Koji Izutsu; Yusuke Sato; Yasunori Ohta; Junichi Furuta; Seiichi Shimizu; Takuya Komeno; Yuji Sato; Takayoshi Ito; Masayuki Noguchi; Emiko Noguchi; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Kazumi Suzukawa; Toru Nanmoku; Yuichi Hasegawa; Osamu Nureki; Satoru Miyano; Naoya Nakamura; Kengo Takeuchi; Seishi Ogawa; Shigeru Chiba
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307

6.  TET proteins and the control of cytosine demethylation in cancer.

Authors:  Laurianne Scourzic; Enguerran Mouly; Olivier A Bernard
Journal:  Genome Med       Date:  2015-01-29       Impact factor: 11.117

7.  IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.

Authors:  Chao Wang; Timothy W McKeithan; Qiang Gong; Weiwei Zhang; Alyssa Bouska; Andreas Rosenwald; Randy D Gascoyne; Xiwei Wu; Jinhui Wang; Zahid Muhammad; Bei Jiang; Joseph Rohr; Andrew Cannon; Christian Steidl; Kai Fu; Yuping Li; Stacy Hung; Dennis D Weisenburger; Timothy C Greiner; Lynette Smith; German Ott; Eleanor G Rogan; Louis M Staudt; Julie Vose; Javeed Iqbal; Wing C Chan
Journal:  Blood       Date:  2015-08-12       Impact factor: 25.476

8.  The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.

Authors:  François Lemonnier; Rob A Cairns; Satoshi Inoue; Wanda Y Li; Aurélie Dupuy; Sophie Broutin; Nadine Martin; Virginie Fataccioli; Romain Pelletier; Andrew Wakeham; Bryan E Snow; Laurence de Leval; Anais Pujals; Corinne Haioun; Angelo Paci; Erica R Tobin; Rohini Narayanaswamy; Katherine Yen; Shengfang Jin; Philippe Gaulard; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 12.779

9.  DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.

Authors:  L Scourzic; L Couronné; M T Pedersen; V Della Valle; M Diop; E Mylonas; J Calvo; E Mouly; C K Lopez; N Martin; M Fontenay; A Bender; S Guibert; P Dubreuil; P Dessen; N Droin; F Pflumio; M Weber; P Gaulard; K Helin; T Mercher; O A Bernard
Journal:  Leukemia       Date:  2016-02-15       Impact factor: 11.528

10.  Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression.

Authors:  Olivier Hermine; Claudine Pique; Ambroise Marçais; Laetitia Waast; Julie Bruneau; Katia Hanssens; Vahid Asnafi; Philippe Gaulard; Felipe Suarez; Patrice Dubreuil; Antoine Gessain
Journal:  Oncotarget       Date:  2016-11-26
View more
  9 in total

1.  Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators.

Authors:  Kevin S Tanager; Jovian Yu; Brian C-H Chiu; Timothy C Carll; Alexandra H Tatarian; Peter Riedell; Sonali Smith; Justin Kline; Girish Venkataraman
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

2.  Small Molecule Inhibitors of TET Dioxygenases: Bobcat339 Activity Is Mediated by Contaminating Copper(II).

Authors:  Nicholas A Weirath; Alexander K Hurben; Christopher Chao; Suresh S Pujari; Tao Cheng; Shujun Liu; Natalia Y Tretyakova
Journal:  ACS Med Chem Lett       Date:  2022-04-21       Impact factor: 4.632

Review 3.  Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality.

Authors:  Adrien Krug; Gamze Tari; Aymen Saidane; Philippe Gaulard; Jean-Ehrland Ricci; François Lemonnier; Els Verhoeyen
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

Review 4.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 5.  TET methylcytosine oxidases: new insights from a decade of research.

Authors:  Chan-Wang J Lio; Xiaojing Yue; Isaac F Lopez-Moyado; Mamta Tahiliani; L Aravind; Anjana Rao
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

6.  Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS.

Authors:  Gareth P Gregory; Michael Dickinson; Costas K Yannakou; Jonathan Wong; Piers Blombery; Greg Corboy; Lev Kats; Tim M E Crozier; Beena Kumar; H Miles Prince; Stephen S Opat; Jake Shortt
Journal:  Hemasphere       Date:  2019-03-01

7.  Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma.

Authors:  Kamel Laribi; Alix Baugier de Materre; Yamina Touileb; Charles Boursot; Jeremy Sandrini; Doriane Cavalieri; Cédric Pastoret; Laurence de Leval; Olivier Tournilhac
Journal:  Hemasphere       Date:  2022-02-01

8.  Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.

Authors:  Jianming Shao; Sihan Wang; Diana West-Szymanski; Jason Karpus; Shilpan Shah; Siddhartha Ganguly; Janice Smith; Youli Zu; Chuan He; Zejuan Li
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

Review 9.  New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP.

Authors:  Rana Mhaidly; Adrien Krug; Philippe Gaulard; François Lemonnier; Jean-Ehrland Ricci; Els Verhoeyen
Journal:  Oncogenesis       Date:  2020-08-14       Impact factor: 7.485
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.